Increasing attention has been paid to prognosis-associated molecular markers in gliomas, such as 1p19q co-deletion, IDH mutations, and p53 mutation, as their application in clinical practice for gliomas has been demonstrated [22]. Here, TP53 is linked to central nervous system cancer.